Purpose: Arzoxifene, a new selective estrogen receptor modulator with strong breast antiestrogen activity and absence of uterine agonist activity, was explored as a potential chemoprevention agent. We performed a multi-institutional evaluation of arzoxifene in women with newly diagnosed ductal carcinoma in situ or T1/T2 invasive cancer.
INTRODUCTION
Arzoxifene (LY353381) is a third-generation selective estrogen receptor modulator similar to raloxifene but modified to improve bioavailability as well as estrogen antagonist potency in the breast and uterus (1) . In vitro and xenograft studies have shown arzoxifene to be more potent than tamoxifen, 4-OH tamoxifen, or raloxifene in inhibiting the growth of tamoxifensensitive, estradiol-stimulated MCF-7 cells (2) . Arzoxifene also was able to suppress the growth of T47D tamoxifen-resistant tumors but not MCF-7 tamoxifen-resistant tumors in xenograft models (3) . The two tamoxifen-resistant models differ in that the resistant MCF-7 cells have reduced levels of the estrogen receptor corepressor NCOR, whereas resistant T47D cells have increased levels of estrogen receptor coactivators such as AIB1 (3) (4) (5) . Arzoxifene was found to be more effective than equimolar doses of raloxifene and equivalent to tamoxifen in the nitrosomethylurea rat breast cancer prevention model (2) . Preclinical studies in ovariectomized rats indicate favorable effects on cholesterol, bone mineral density, and uterine weight, which support the potential utility of arzoxifene as a prevention agent. Indeed, in preclinical studies arzoxifene was more potent than raloxifene in the prevention of bone loss (1, 6) . Low-dose arzoxifene and a novel rexinoid have been demonstrated to be synergistic in the rat model of breast cancer (7) .
Animal models predicted antitumor activity at equivalent human doses of 10 mg/day (2) . Studies in healthy postmenopausal volunteers and in women with metastatic disease indicated that the pharmacokinetics of arzoxifene were linear over a wide dose range (8, 9) . Pharmacodynamic changes were observed starting at the 10 mg per day dose and included reduced levels of low-density lipoprotein cholesterol, serum fibrinogen, antithrombin III activity, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and the bone turnover biomarkers osteocalcin and urine type I collagen fragments, whereas an increase was observed for sex hormone binding globulin (9) .
Significant antitumor activity has been reported for tamoxifen-naive or -sensitive subjects in Phase II trials of women with metastatic disease. Baselga et al. (10) reported a complete and partial response rate of 43% for arzoxifene at 20 mg/day and 27% for arzoxifene at 50 mg/day in a cohort with a median age of 70 and in whom only 9% had received prior tamoxifen. Only 10% of tamoxifen refractory subjects responded to 20 -50 mg daily arzoxifene (11) . No uterine agonist effects were reported in women who had not been exposed to tamoxifen previously (11) .
Despite preclinical and clinical evidence of partial crossresistance with tamoxifen, the demonstrated efficacy of arzoxifene in advanced breast cancer, lack of uterine agonist activity, and favorable pharmacodynamic effects on bone and lipids make it an attractive selective estrogen receptor modulator for prevention.
A number of studies have demonstrated that selective estrogen receptor modulators likely to be effective in breast cancer treatment and prevention will show a reduction in proliferation in estrogen receptor-positive tumors after 2-4 weeks of treatment (12) (13) (14) (15) (16) .
Therefore, before beginning large-scale prevention studies with arzoxifene, a short-term Phase IA/IB preoperative biomarker modulation study in women with newly diagnosed breast cancer was initiated by a multi-institutional group as part of a Division of Cancer Prevention, National Cancer Institutesponsored contract. In the Phase IA portion of the trial, women with core biopsy evidence of ductal carcinoma in situ and/or invasive cancer were randomized to one of several doses of arzoxifene in the interval between core biopsy and re-excision. The purpose of the Phase IA trial was to select the lowest dose associated with a reduction in proliferation as well as identify other modulated biomarkers consistent with the presumed mechanism of action (17, 18) . In the Phase IB trial, the dose selected from the Phase IA trial was compared in a randomized double-blind fashion to placebo with the primary end point of reduction in proliferation (17) .
We report the results of Phase IA and Phase IB biomarker modulation trials of arzoxifene administered to women with hormone receptor-positive ductal carcinoma in situ and/or T1-T2 invasive breast cancer in the interval between diagnostic biopsy and definitive surgical treatment.
MATERIALS AND METHODS
Study Design. In the Phase IA trial, eligible pre-and postmenopausal women were randomized to one of three doses of arzoxifene administered daily in the planned interval between biopsy and re-excision. The planned interval was not altered by participation in the trial, but subjects were not eligible if the interval was anticipated to be Ͻ2 weeks or Ͼ6 weeks. Women not wishing to receive drug but who were otherwise eligible and willing to participate served as nonrandomized no-treatment controls. Women on hormone replacement therapy discontinued this medication before study entry. Doses selected for the Phase IA trial were 10, 20, and 50 mg/day (10-mg and 50-mg tablets supplied by Eli Lilly via the National Cancer Institute). Dose selection was based on the favorable pharmacodynamic effects of arzoxifene in doses as low as 10 mg/day (9) and reported responses at 20 and 50 mg/day in advanced breast cancer. Arzoxifene has a terminal elimination half-life of 30 -35 h (9) . On the basis of the pharmacokinetic profile of arzoxifene, steady state was not predicted to be reliably reached during a 2-4 week trial using once daily dosing; therefore, a loading dose consisting of twice the assigned daily dose was used on day 1 and day 2 for both the Phase IA and Phase IB trials. Subjects were instructed to take their study drug with a meal. Once a subject had been randomly assigned a drug dose, the dose a subject was receiving was known to investigators.
The Phase IB trial as originally activated was a doubleblind, three-way, 1:1:1 randomization among arzoxifene 20 mg/day, tamoxifen 20 mg/day, and matching placebos for both drugs (supplied by McKesson Laboratories under contract to the National Cancer Institute). The trial was restricted to postmenopausal women who had not received hormone replacement therapy within 30 days of biopsy. However, accrual was extremely slow (14 subjects in 8 months) due in part to the exclusion of women who had received hormone replacement therapy within 30 days of biopsy and the difficulty of explaining a three-way randomization to potential subjects. Consequently, the protocol was amended to allow women who had received hormone replacement therapy in the peribiopsy period to enter the study providing hormone replacement therapy was discontinued before study entry (subjects were stratified according to hormone replacement therapy use within 30 days of biopsy). The protocol was also changed to a design of two sequential phases: 60 subjects in a 2:1 randomization between arzoxifene and matching placebo to be followed by 60 subjects in a 2:1 randomization between tamoxifen and matching placebo. Subsequently, a decision was made to omit the tamoxifen phase and to instead continue subject accrual with a target accrual of ϳ60 subjects on the arzoxifene arm. The blinded assignment between arzoxifene and placebo was maintained throughout the study and subsequent analysis. Only the biostatistician at University of Kansas Medical Center not otherwise associated with this trial who prepared the randomization assignments and the investigational pharmacists at each participating institution were aware of the study agent assignments. For analysis, the study agent assignments were revealed to the University of Kansas Medical Center biostatisticians conducting the analyses. Table 1 summarizes study design, eligibility, and biomarker endpoints for the Phase IA and Phase IB trials.
Subject Selection/Eligibility. Eligible subjects for both Phase IA and IB trials were women with a clinical ductal carcinoma in situ, T1, or T2/N0 tumor, who had recently undergone a core or excisional biopsy in which tumor was present at the margins and who were anticipating a minimum of 2 weeks between biopsy and re-excision. Premenopausal women eligible for the Phase IA trial must have had a negative pregnancy test and must have been willing to use a barrier type of contraception during trial participation. When hormone replacement therapy (or oral contraceptive) use before diagnosis was allowed, it was required that they be discontinued before study entry. To be eligible, the biopsy must have been fixed in 10% neutralbuffered formalin according to a prescribed protocol and the tumor judged as either non-high grade according to the institutional pathologist and/or found to be estrogen receptorϩ or progesterone receptorϩ by institutional standards with enough tumor remaining in the tissue block for 24 -36 additional sections. Women were required to be in generally good health with no prior history of deep venous thrombosis, stroke, or uterine cancer. Normal organ function was required with Ͼ10 g/dl hemoglobin, Ͼ1000/l absolute granulocyte count, Ͻ1.5 mg/dl creatinine, Ͼ3.0 g/dl albumin, Ͻ1.5 mg/dl bilirubin, Ͻ100 units/l aspartate aminotransferase, and Ͻ200 units/l alkaline phosphatase.
Serum Biomarkers. An average of 15 ml of serum was obtained before entry and again at the off-study point for estradiol, estrone, FSH, LH, insulin-like growth factor (IGF-I), insulin-like growth factor binding protein type 3 (IGFBP-3), progesterone, sex hormone binding globulin, and thyroxinebinding globulin for the Phase IA trial. The same assays were performed for the Phase IB trial, with the exception that progesterone and thyroxine-binding globulin were omitted. Serum was stored at Ϫ70 to Ϫ80°C until analysis, with pre-and poststudy specimens assayed in the same run. Selective estrogen receptor modulators such as tamoxifen had been described previously as modulating the risk biomarkers IGF-I, IGFBP-3, and sex hormone binding globulin (19 -21) . Modulation of thyroxinebinding globulin and sex hormone binding globulin were also considered potential markers of selective estrogen receptor modulator biological activity without regard to efficacy. Hormone assays were performed to determine whether the systemic hormone levels were substantially altered between the study entry time point and the re-excision time point. For the Phase IA trial, serum assays were conducted at Midwest Research Institute (Kansas City, MO) using radioimmunoassays (for estradiol, estrone, and progesterone) or immunoradiometric assays (for FSH, IGF-1, IGFBP-3, sex hormone binding globulin, and thyroxine-binding globulin). For the Phase IB trial, serum assays were conducted at the Center for Reproductive Endocrinology Laboratories, University of Kansas Medical Center (Dr. Paul Terranova) using enzyme immunoassays from Diagnostic Systems Laboratories, Inc. (Webster, TX; estradiol, estrone, FSH, LH, IGF-I, and IGFBP-3) and Diagnostic Biochemicals (London, Ontario, Canada; sex hormone binding globulin).
Tissue Assays. The tissue biomarkers assessed in Phase IA and IB are listed in Table 2 . In addition to the primary study end points, a number of other tissue biomarkers were assessed that might be predictive and/or reflective of successful selective estrogen receptor modulator treatment, including predictive markers such as estrogen receptor, progesterone receptor, and Her-2/neu (22, 23) ; markers of angiogenesis such as thrombospondin, CD31, and p53 incorporated into an angiogenesis index, vascular endothelial growth factor, and microvessel density (24 -26) ; and growth and survival signaling markers such as bcl-2, phosphorylated extracellular regulated kinase, tumor necrosis factor ␣, and insulin-like growth factor receptor (27) (28) (29) (30) Tissue was fixed in 10% neutral-buffered formalin at the individual sites for Ն6 h but Յ24 h and then processed to paraffin blocks. After sufficient tissue had been used at the site for diagnostic purposes, blocks were sent to University of Kansas Medical Center for central sectioning, staining and interpretation at the University of Kansas Medical Center Pathology Research Laboratories by O. W. T. Institutions were allowed to send unstained tissue sections on slides provided these were processed and mailed such that slides could be stained within 72 h of sectioning of the block at the central laboratory at University of Kansas Medical Center. Staining and assessment of pre-and poststudy tissue assays were performed together. Sectioning of the block for all of the assays was performed at the same time. Automated stainers (Dako, Ventana) were used for staining all of the specimens, and known positive and negative controls were included with each run. Assessments were done with the CAS 200 image analyzer for Ki-67 (MIB-1 antibody), proliferating cell nuclear antigen (PCNA), estrogen receptor, progesterone receptor, and p53 and produced values for the percentage of cells staining positively. Manual assessment was used for other biomarkers using an immunochemistry weighted index score (range, 0 -4) developed by our immunochemistry consultant (W. E. G.; Ref. 31) . Before beginning the study, all of the immunochemistry procedures were validated and approved. The antibodies used are listed in Table 2 . For the Phase IA trial, assessment of nuclear morphometry was also performed by O. W. T, B. F. K., and J. W. B. using an automated image analysis system (BLISS; Bacus Laboratories, Inc., Elmhurst, IL). Fuelgen-stained specimens were scanned, areas of interest marked, and a z-score computed that incorporated a number of parameters and represents their deviation from normalcy (32) . For the Phase IA trial, a subset of subjects was evaluated by J. P. F. for change in angiogenesis index (24) .
For the Phase IB trial, nuclear morphometric assessment was omitted because it was noninformative in the Phase IA trial. The angiogenesis index was omitted because it was cumbersome and required multiple slides, and the microvessel density was substituted. Several new assays were added (phosphorylated extracellular regulated kinase, tumor necrosis factor ␣, and insulin-like growth factor 1 receptor), which might be informative regarding selective estrogen receptor modulator resistance (33) (34) (35) (36) (37) . PCNA, Ki-67, estrogen receptor, progesterone receptor, p53, and Her-2/neu were analyzed with validated programs on an Automated Cellular Imaging System (ChromaVision Medical Systems, Inc., San Juan Capistrano, CA) image analyzer and were verified manually. However, antibodies with predominately cytoplasmic and/or membrane localization (epidermal growth factor receptor, Bcl-2, insulin-like growth factor receptor, phosphorylated extracellular regulated kinase, and tumor necrosis factor ␣) were assessed manually by consensus scoring (weighted index score) on a 0 -4 scale. Microvessel density (by factor VIII antibody) evaluation was performed by assessing the areas of tumor microvessel density in a representative section. Vessels were counted in five random highpowered fields in the selected area and the mean vessel count from the five fields used. At least 1000 epithelial cells were analyzed for each marker.
Accrual Goals. Accrual goals for the Phase IA trial were 10 subjects in each of the three (10, 20, and 50 mg/day) arzoxifene arms, and the nonrandomized no-treatment control group, for whom prestudy and poststudy specimens were available and change in the primary end point (proliferation) could be evaluated. With this number of subjects, if a reduction in proliferation (Ki-67 or PCNA) was seen in at least 8 subjects, we would be 89% confident that the probability of favorable modulation is at least 50%.
The accrual goal for the amended Phase IB trial was 80 subjects from which 60 subjects would be evaluable for the primary end point biomarkers. This accrual goal was based on the number of subjects needed to detect a large effect size of 0.8 SDs in change in the proportion of cells expressing a proliferation maker between the control and the treatment groups with an 80% power and type I error rate of 5%. From the Phase IA results, this would project to an absolute decrease from 10% at baseline to 4% or 5% at re-excision in the proportion of cells expressing Ki-67 or PCNA, respectively.
Data Capture and Entry. Clinical data were entered onto case report forms at individual sites, and audited data were entered into a computerized database at CCS Associates (Mountain View, CA). The clinical data were down loaded electronically into a joint biomarker and clinical database housed in the Biostatistical Unit of the University of Kansas Medical Center. Tissue biomarker and serum biomarker data were downloaded electronically into this database as well.
Statistical Analyses. For the Phase IA and Phase IB trials, categorical variables were summarized by frequencies and percentages, and quantitative variables were summarized by medians and ranges. For the Phase IA trial, quantitative variables were compared among the four groups using the KruskalWallis test. The Wilcoxon rank-sum test was used to perform pair-wise comparisons on quantitative variables that were globally different among the four groups. Fisher's exact test was used to compare categorical variables among the four groups. For the Phase IB trial, except for the evaluation of the primary endpoints (modulation of proliferation index and frequency of adverse events), all of the analyses were considered as exploratory. Thus, no corrections for multiple comparisons were made. Quantitative variables were compared between the two groups using the Wilcoxon rank-sum test. The two-sample t test was also performed as per protocol. Whereas the conclusions are identical for each procedure, given the skewness of the distributions for many variables, the Wilcoxon rank-sum test was the preferred method of analysis. Categorical variables were com- 
RESULTS

Results of the Phase IA Trial
Accrual and Participating Institutions. From November 1998 to December 1999, 50 subjects were entered into the Phase IA trial after signing appropriate informed consents as approved by the site Institutional Review Board. At least 315 potential subjects were screened to accrue this number of subjects (the uncertainty resulted from variations in the definition and reporting of screening between sites). Accrual distribution included four from University of Kansas Medical Center, 15 from Loyola University Medical Center, 14 from US Oncology, 8 from Ohio State University, and 3 each from Cleveland Clinic Foundation, University of California Los Angeles, and Desert Comprehensive Cancer Center.
Forty women with newly diagnosed ductal carcinoma in situ, T1, or T2 tumors were randomized to 10, 20, and 50 mg of arzoxifene daily (13, 13, and 14 subjects, respectively). In addition, 10 subjects were registered as nonrandomized, notreatment controls. Five subjects were not evaluable for tissue based biomarkers, because there was no residual tumor available for analysis in the re-excision specimen (3 subjects) or because the biopsy was both estrogen-receptor and progesterone-receptor negative (2 subjects) by immunohistochemistry performed at University of Kansas Medical Center. Thus, 45 Phase IA subjects were evaluable for the primary biomarker endpoint including 8 controls, 11 on the 10-mg arm, 13 on the 20-mg arm, and 13 on the 50-mg arm. Characteristics of these subjects are listed in Table 3 . Median age was 61; 84% were postmenopausal. Fifteen of 37 (41%) subjects on study drug and 3 of 8 (38%) no-treatment controls had received hormone replacement therapy within 30 days of biopsy. Eighty percent of biopsy specimens were grade I or II. Seventy-eight percent of women had invasive cancer in both their original biopsies and re-excision specimens, whereas 13% had ductal carcinoma in situ in both specimens. For 9% of subjects, the submitted biopsy and re- * Interval between entry on study and re-excision surgery and considered to be drug-related. † Includes hot flashes and sweating. excision specimens differed in that one contained only invasive cancer and the other only ductal carcinoma in situ. Median on study interval was 15 days (range, 10 -42 days).
Adverse Events for the Phase IA Trial. Reported adverse events for all 40 of the subjects during the time they were receiving arzoxifene were mild (grade 2 or less) and did not differ between the three dose levels ( Table 4 ). The most frequent adverse effects were hot flashes, mild gastrointestinal effects, headache, and breast pain, the latter most likely related to biopsy. Three subjects who had received 10 mg of arzoxifene required hospitalization for complications from surgery, but this was not considered to be related to arzoxifene.
Change in Serum and Tissue Markers for the Phase IA Trial. Baseline serum and tissue biomarker values are given in Table 5 for the 45 tissue biomarker evaluable subjects (8 control and 37 arzoxifene). For several variables (PCNA, estrogen Fig. 1 Number of subjects on Phase IA trial who exhibit a change (prestudy to poststudy) in serum hormone or growth factor levels. The number above the bars indicate the number of subjects in whom the change was an "improvement" (in the direction that would reduce breast cancer risk); the numbers below the bars indicate subjects in whom no change was observed or the change was in an unfavorable direction. Ⅺ, controls; f, arzoxifene. IGFBP, IGF, binding protein; SHBG, sex hormone binding globulin; TBG, thyroxine-binding globulin. Fig. 2 Number of subjects on Phase IA trial who exhibit a change (biopsy to re-excision) in tissue biomarkers. The numbers above the bars indicate the number of subjects in whom the change was an "improvement" (in the direction that would reduce breast cancer risk or would be consistent with the presumed mechanism of action of arzoxifene); the numbers below the bars indicate subjects in whom no change was observed or the change was in an unfavorable direction. Ⅺ, controls; f, arzoxifene. ER, estrogen receptor; PR, progesterone receptor; AI, angiogenesis index; EGFR, epidermal growth factor receptor. receptor, and Her-2/neu) there were differences between groups at baseline, particularly between the control and the three arzoxifene groups. It was observed that several variables exhibited changes in a direction that would be "favorable" from a standpoint of a risk factor for breast cancer (e.g., a decrease in serum IGF-I) or as consistent with the presumed mechanism of action of arzoxifene (e.g., a decrease in proliferation index). Changes in a favorable direction for a majority of subjects receiving arzoxifene were observed for serum levels of IGF-I, IGFBP-3, IGF-1:IGFBP-3 molar ratio, sex hormone binding globulin, and thyroxine-binding globulin (Fig. 1) ; and for tissue expression of Ki-67, Bcl-2, Her-2/neu, epidermal growth factor receptor in benign tissue, and PCNA (Fig. 2) . When separated by dose group, several markers (IGF-1:IGFBP-3 molar ratio, sex hormone binding globulin, thyroxine-binding globulin, and PCNA) exhibited favorable changes in Ͼ80% of subjects at one or more dose levels (Table 6 ). For the serum markers, it appeared that the 10-mg dose was not as effective as either the 20-mg or 50-mg doses in producing a favorable change. Importantly, for the tissue biomarker PCNA, all 13 of the subjects receiving 20 mg of arzoxifene exhibited a decrease in expression (Fig. 3) .
Absolute changes in serum and tissue biomarker expression are listed in Table 7 for control subjects and subjects in the individual drug dose groups. Compared with the no-treatment control group, significant changes (pre-post study) were seen in sex hormone binding globulin, thyroxine-binding globulin, and PCNA for both the 20-and 50-mg dose groups using the Wilcoxon rank-sum test (P ϭ 0.0001).
The possibility was considered that discontinuation of hormone replacement therapy in the peribiopsy period may have been responsible for some of the observed change in Ki-67 and PCNA expression between biopsy and re-excision for postmenopausal women. Change in Ki-67 and PCNA may also have been affected in premenopausal women if the initial biopsy was performed in a different portion of their menstrual cycle than re-excision. In a secondary analysis, we excluded women considered to have been hormonally confounded on the basis of estradiol levels in the premenopausal range at biopsy and in the postmenopausal range at re-excision or premenopausal women documented to have been at a different phase of the menstrual cycle at biopsy than at re-excision. Applying these criteria, 33 women (4 controls and 29 arzoxifene) considered nonhormonally confounded were retained for the secondary analysis. A significant difference between nontreated controls and subjects that received arzoxifene was still observed for sex hormone binding globulin, thyroxine-binding globulin, and absolute changes in PCNA using parametric and nonparametric analysis (Table 8) . Notably, the 20-mg dose provided the greatest numerical increase in sex hormone binding globulin and the greatest numerical decrease in PCNA. Upon completion of analysis of the Phase IA trial, four general observations were made. First, arzoxifene produced little in the way of adverse events, with no evidence for a relationship to drug dose. Second, levels of serum markers considered as drug effect biomarkers or risk biomarkers appeared to be favorably altered in a higher proportion of subjects that received 20 mg or 50 mg arzoxifene than those receiving only 10 mg daily. Third, proliferation (PCNA expression) decreased in all of the subjects that received 20 mg of arzoxifene daily. Lastly, the use of no-treatment controls (rather than subjects randomized to placebo) resulted in a group of subjects that differed from subjects receiving drug. In particular, there were significant differences in baseline values for two important tissue biomarkers (PCNA and estrogen receptor). These differences could impact the assessment of modulation of biomarkers over the study interval and the subsequent analyses. Thus, any conclusions regarding differences between control and drug groups were viewed with caution and used only for purposes of designing the subsequent Phase IB trial.
On the basis of these Phase IA results, the 20-mg dose of arzoxifene was selected for the subsequent randomized, placebocontrolled Phase IB trial.
Results of the Phase IB Trial
Accrual and Participating Institutions. From June 5, 2000 to July 19, 2002 , 81 subjects were entered onto the Phase After entry of the first 14 subjects, the protocol was amended due to slow accrual. The tamoxifen arm was discontinued, and a weighted randomization scheme was used such that 2 subjects were randomized to arzoxifene for every 1 randomized to placebo. Of the 81 subjects accrued to the study, 5 were accrued to tamoxifen in the preamendment portion, and the remaining 76 were randomized between arzoxifene and placebo. Seven subjects were excluded from the toxicity and pharmacodynamic analysis due to randomization to tamoxifen (5), withdrawal from study before receipt of any drug (1), or receipt of both arzoxifene and tamoxifen (1). Thus, 74 subjects were evaluable for toxicity analysis and serum pharmacodynamic analysis for the placebo and arzoxifene arms. The median age of the 74 subjects evaluable for toxicity and serum pharmacodynamic parameters was 63 years. The median baseline estradiol level was 28 pg/ml, and 46% of subjects had been taking hormone replacement therapy within 30 days of biopsy, including 23 of 47 (49%) subjects randomized to study drug and 11 of 27 (41%) subjects randomized to placebo. Median time from biopsy to study entry was 10 days (range, 0 -45), and median on study interval was 20 days (range, 9 -55). There were no significant differences for demographics, tumor characteristics, or intervals between various study events (Table 9 ) between the arzoxifene and placebo groups. Adverse Events for the Phase IB Trial. Analysis of adverse events was performed for the 74 subjects randomized to arzoxifene or placebo who received study drug. Similar to the Phase IA trial, reported adverse events were mild with 18% of subjects reporting no effects, 40% grade 1, 36% grade 2, and 6% grade 3. There were no significant differences between the arzoxifene group and the placebo group in reported adverse events, either globally or for specific types of toxicities (Table  10 ). The exception to this was the incidence of leg cramps and myalgias, which were more frequent in the placebo arm than the arzoxifene arm (P ϭ 0.045 and 0.0087, respectively). Surgical complications such as hematomas, seromas, wound dehiscence, and infection were no more common in the arzoxifene group than in the placebo group (12% for both). Five serious adverse events (hypotension, hemorrhage, sinus tachycardia with arrhythmia, wound infection, and acute otitis) were reported in 5 subjects after planned re-excision surgery and were not considered to be study agent-related. The sinus tachycardia and the wound infection events were in subjects randomized to arzoxifene; the other three events were in subjects randomized to placebo.
Change in Serum Pharmacodynamic Parameters for the Phase IB Trial. Baseline values for serum pharmacodynamic parameters for the 74 placebo and arzoxifene subjects are summarized in Table 11 . There was no significant difference in baseline values between the two groups. Changes in estradiol, estrone, FSH, LH, IGF-I, IGFBP-3, IGF-1:IGFBP-3 molar ratio, and sex hormone binding globulin for placebo and arzoxifene groups are given in Table 12 . Compared with placebo, arzoxifene-treated subjects had significantly greater increases in sex hormone binding globulin (P ϭ 0.0015); and greater decreases in LH (P ϭ 0.03), IGF-I (P ϭ 0.0004), and IGF-I:IGFBP-3 molar ratio (P ϭ 0.0066).
Change in Tissue Biomarkers for the Phase IB Trial. Subjects randomized to arzoxifene or placebo were evaluable for the primary study endpoint of change in proliferation if the tumors were estrogen receptor ϩ and/or progesterone receptor ϩ at baseline, and there were malignant cells in both the preand poststudy specimens. Sixteen subjects were not evaluable for tissue-based biomarkers, because there was no residual tumor available for analysis in the biopsy and/or re-excision specimen (11 subjects), because the biopsy was both estrogenreceptor and progesterone-receptor negative (3 subjects) by immunohistochemistry performed at University of Kansas Medical Center or because Ki-67 values were not available for both biopsy and re-excision specimens (2 subjects). Of the 58 subjects evaluable for modulation of Ki-67, 37 were randomized to arzoxifene and 21 to placebo; for 54 subjects with pre-post values for PCNA, 35 were randomized to arzoxifene and 19 to placebo. Distributions of demographic characteristics (Table 13) were similar to the larger (74 subjects) group evaluated for toxicity. Median age was 64 (range, 44 -86) years; 42% had been on hormone replacement therapy within 30 days of biopsy; median time from biopsy to study entry was 10 (range, 0 -45) days; and median on study interval was 20 (range, 9 -55) days. Forty seven (81%) had invasive cancers evaluated, and 11 (19%) ductal carcinoma in situ; 45 (78%) had non-high-grade tumors.
Distributions of baseline serum hormone levels (Table 14) were also similar to the larger (74 subjects) group evaluated for serum hormone pharmacodynamics. There were no significant differences between the arzoxifene and placebo groups for baseline biomarker expression of any serum or tissue biomarker, including the proliferation indices. However, it should be noted that values for proliferation indices were low. The median values for proportion of cells expressing Ki-67 and PCNA at baseline were of 6% and 5% for placebo, and 7% and 10% for arzoxifene, respectively. Table 15 compares the changes in serum and tissue biomarkers for the 58 evaluable subjects. Significant differences were observed between the placebo and arzoxifene groups for serum LH, sex hormone binding globulin, IGF-I, the molar ratio of IGF-I:IGFBP-3, and tumor estrogen receptor (P Յ 0.01). No significant differences were observed between placebo and arzoxifene groups for the main study endpoint, tumor cell proliferation, despite decreases in both Ki-67 and PCNA in the arzoxifene group. The median change in the proportion of cells expressing Ki-67 was Ϫ1% for placebo and Ϫ2% for arzoxifene; the corresponding relative changes were Ϫ20% and Ϫ25%, respectively. The median change in the proportion of cells expressing PCNA was 0% for placebo and Ϫ3% for arzoxifene; the corresponding relative changes were Ϫ23% and Ϫ40%, respectively.
Similar to the Phase IA trial, a secondary analysis was performed to assess the potential confounding effects on proliferation of stopping the hormone replacement therapy in the peribiopsy period. Twenty-five of the 58 tissue biomarker evaluable subjects had been on hormone replacement therapy at the time of biopsy or within 30 days before biopsy but stopped before study entry (median of 4 days after biopsy). These included 7 of 21 (33%) subjects in the placebo group and 18 of 37 (49%) subjects in the arzoxifene group. As anticipated, differences were observed in Ki-67 modulation between subjects on hormone replacement therapy versus those not on hormone replacement therapy within 30 days of biopsy. Subjects not on hormone replacement therapy exhibited a median relative decrease in the proportion of cells expressing Ki-67 of 8% for arzoxifene versus an increase of 3% for placebo and a median relative decrease in the proportion of cells expressing PCNA of 25% for arzoxifene versus an increase of 3% for placebo. Subjects who had received hormone replacement therapy but then discontinued use exhibited a relative decrease in the median proportion of cells expressing Ki-67 of 53% for arzoxifene versus 76% for placebo and a relative decrease in the median proportion of cells expressing PCNA of 50% for arzoxifene versus 56% for placebo. These results would appear to indicate a strong antiproliferative effect of stopping hormone replacement therapy independent of any effect of arzoxifene.
DISCUSSION
Reduction in the proportion of tumor cells expressing Ki-67 after 2-3 weeks of tamoxifen has been correlated with later clinical response in women with breast cancer (12, 15) . Several European studies have used preoperative models similar to our Phase IA/IB trial and found reductions in Ki-67 after 2-4 weeks of treatment with a selective estrogen receptor modulator (14, 16) .
In the trial reported by Decensi et al., a 15% (95% confidence interval, 0 -24%) median relative reduction from baseline in the proportion of cells expressing Ki-67 was observed for 120 estrogen receptor ϩ subjects randomized to one of three doses of tamoxifen for 4 weeks, whereas a relative increase of 13% (95% confidence interval, Ϫ3.3-33%) was observed in 29 estrogen receptor ϩ nonrandomized controls (16) . Dowsett et al. (14) reported a 21% median relative reduction from baseline in the proportion of cells expressing Ki-67 for 42 subjects randomized to 2 weeks of 60 mg/day raloxifene versus a median relative increase of 7% in 36 subjects randomized to placebo. Dowsett et al. (13) also reported a 35% mean relative reduction from baseline in the proportion of cells expressing Ki-67 for 30 subjects randomized to 2-3 weeks of idoxifene versus a 6% mean relative increase in 27 subjects randomized to placebo. The trial reported by Decensi et al. (16) differed from ours in that three times as many subjects were entered into the study and were treated for twice as long. The two studies reported by Dowsett et al. (13, 14) differed from ours in that eligible women could not have received hormone replacement therapy for at least 3 months before initial biopsy.
In our IA arzoxifene study, a decrease in Ki-67 from baseline was observed in only 54% of subjects, whereas PCNA was decreased in Ͼ80% of subjects at the higher dose levels. PCNA is more likely than Ki-67 to be expressed in cells in early G 1 and/or in cells that have traversed the cell cycle recently but are currently in G 0 (38 -40) . Thus, when proliferation is low, as observed in the predominately well-differentiated tumors in this clinical model, PCNA may be a more sensitive indicator of proliferation than Ki-67 (41, 42) . Unfortunately, PCNA detection varies with length of fixation and processing conditions. Moreover, assessment of positive staining is more susceptible to interpretive variance than Ki-67 (43) . Although the arzoxifene dose for our Phase IB trial was selected on the basis of PCNA, Ki-67 is considered to be more reproducible and consistent in its pattern of staining (42, 44, 45) and, thus, both were retained as measures of proliferation. In the Phase IB trial, the baseline expression of Ki-67 and PCNA were similar, both in the placebo group and in the arzoxifene group. For women randomized to arzoxifene in the Phase IB trial, we observed a median relative reduction of 25% in the proportion of tumor cells expressing Ki-67, similar to that reported for tamoxifen, raloxifene, and idoxifene, as well as a 46% reduction in PCNA. However, unlike the trials reported by Dowsett et al. (13, 14) , a median relative reduction of 20% in Ki-67 and 23% in PCNA was also observed in the randomized placebo group. Thus, for our primary endpoint proliferation, there was no significant change between 20 mg/day arzoxifene and placebo. Subgroup analysis indicates that the lack of significant reduction in proliferation index in women randomized to arzoxifene versus those randomized to placebo may have been in part secondary to the confounding effects of discontinuance of hormone replacement therapy in the peribiopsy period before re-excision.
Prasad et al. (46) have reported recently on the effects of discontinuing hormone replacement therapy in the interval between core needle biopsy and definitive surgery (re-excision, lumpectomy, or mastectomy) for invasive breast cancer. They found that there was a decrease in Ki-67 expression associated with discontinuation of hormone replacement therapy that was statistically significant when compared with patients that had either not been using hormone replacement therapy before biopsy or who had continued to use hormone replacement therapy until definitive surgery. This effect was observed for tumors that were estrogen receptor ϩ but not for tumors that were estrogen receptor Ϫ.
For those women in our study not on hormone replacement therapy previously, the 3% (Ki-67) or 17% (PCNA) median relative increase for placebo and the 8% (Ki-67) or 30% (PCNA) median relative decrease for arzoxifene are similar to proliferation effects observed in the United Kingdom trials of raloxifene and idoxifene. On the other hand, subjects who had received hormone replacement therapy within 30 days of biopsy exhibited a dramatic reduction in the proportion of cells expressing Ki-67 or PCNA, regardless of whether randomized to placebo or to arzoxifene. This implies that future studies using the preoperative model should not enroll women with estrogen receptor ϩ tumors who have been taking hormone replacement therapy before biopsy if proliferation is to be used as an endpoint and if the hormone replacement therapy is to be discontinued between biopsy and re-excision. Although our Phase IB trial was initially designed to exclude both premenopausal women as well as postmenopausal women who had received hormone replacement therapy recently, accrual problems prompted us to amend the study to allow entry of postmeno- 
